Latest Industry Insights

In this interview, Technology Networks spoke to Dr. Cameron Pitt to learn more about KRAS as a target for cancer therapeutics, avoiding known resistance mechanisms and the effectiveness of two novel KRAS inhibitors.

Change management is becoming an increasingly important part of company culture. This article explores how effective change management can reap significant benefits.

In this opinion piece, Dr. Gen Li discusses how AI and predictive analytics are transforming oncology clinical trials.

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.

Technology Networks spoke with Anjali Pradhan, senior vice president of product management at Mission Bio, to discuss a new application for DNA methylation analysis, and its potential in uncovering new biological insights and biomarkers that may guide the future of cancer research.

At SLAS 2023, Technology Networks spoke with the PerkinElmer Life Sciences and Diagnostics organization to discuss the launch of two new automated platforms. These innovative systems are designed to improve workflows such as high-throughput drug discovery screening and next-generation sequencing library prep through advances in automation technologies.

In this article, we explore how a future generation of scientists a century later took up Dr. Cajal’s call to arms and sought to counter his dire prognostication on the prospect of nerve regeneration.

Renewed efforts to tap cyanobacteria, algae and plants in arenas typically dominated by heterotrophic systems are already beginning to yield fruit. In this article, we explore the inherent value of photosynthetic biotechnologies and their challenges.

Shark-derived squalene is a common adjuvant product found in several approved vaccines. As calls for a sustainable source of squalene increase, researchers are exploring how yeast can be used to produce squalene analogues.

In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.